TP53 and neoplasm: This inhibition demonstrates a marked anti-tumor effect agnostic of tumor histone, TP53, or passenger mutation status, opening a therapeutic avenue that may prove resilient to the intra- and intertumoral heterogeneity that has complicated translational efforts in a molecularly diverse disease entity.